Director, Hanjani Institute for Gynecologic Oncology, Abing-Jefferson Health
Obstetrics & Gynecology
Dr. Mark S. Shahin, MD
|
|
Give Review
Mark S. Shahin is an expert in the field of Obstetrics & Gynecology. He studied medicine at Northwestern University Feinberg School of Medicine. Northwestern University Feinberg School of Medicine is ranked 19 in research and 29 in primary care medicine He has 4 awards "Philadelphia Magazine", "CMS Meaningful Use Stage 1 Certification", "Fellow (FACS)" and "Fellow (FACOG)". Doctor Mark S. Shahin, MD is a published MD. He has 24 papers published. The most current publication "Reproductive sequelae of cancer treatment." He is registered with Medicare.
Publications
- In vitro chemoresponse in metachronous pairs of ovarian cancers.
- A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: A Gyneco...
- We need a new paradigm in gynecologic cancer care: SGO proposes solutions for delivery, quality and reimbursement policies.
- Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study.
- A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primar...
- A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecol...
- A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study.
- A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: a gynecologic oncology gr...
- Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial.
- Anorectal dysfunction after surgical treatment for cervical cancer.
- Phase II evaluation of 3-day topotecan with cyclophosphamide in the treatment of recurrent ovarian cancer.
- Failure of BRCA1 dysfunction to alter ovarian cancer survival.
- Ovarian mixed germ cell tumor with predominance of polyembryoma: a case report with literature review.
- Reproductive sequelae of cancer treatment.
- The glutathione S-transferase M1 genotype in ovarian cancer.
- A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group...
- A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.
- The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma.
- Measurement of vaginal length: Reliability of the vaginal sound--a Gynecologic Oncology Group study.
- p53 Mutations and microsatellite instability in ovarian cancer: Yin and yang.
- The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer.
- Paclitaxel and platinum chemotherapy for ovarian carcinoma during pregnancy.
- Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500.
Schools
NWU FIENBERG SCH OF MED
McGaw Med Center Nw University
University Ia HospsClins
Procedures Preformed
- Colpopexy
- Colposcopy
- Destruction or Excision of Lesion of Cervix (incl. LEEP)
- Destruction or Excision of Vaginal Lesions
- View All
Doctors Specialties
- Gynecologic Oncology
- Obstetrics
- Gynecology
Accepted Insurances
Awards
- Philadelphia Magazine
- CMS Meaningful Use Stage 1 Certification
- Fellow (FACS)
- Fellow (FACOG)
Education
-
McGaw Medical Center of Northwestern University -
Northwestern University Feinberg School of Medicine
Hospital
-
Abington Hospital - Jefferson Health -
Doylestown Hospital -
Thomas Jefferson University Hospital
Drug Facts
| NPI NUMBER | 1568440451 | |
| NPPES Provider LastName | SHAHIN | |
| NPPES Provider FirstName | MARK | |
| NPPES Provider ZIPCode | 190013720 | |
| NPPES Provider State | PA | |
| Specialty Description | Obstetrics/Gynecology | |
| Total Claim Count | 334.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 14.0 | |
| Percent Opioid Claims | 4.19 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1568440451 |
| Last Name Of The Provider | SHAHIN |
| First Name Of The Provider | MARK |
| View All |
Similar Doctors
|
Dr. Lauren W. Milman, MD |
|
|
Dr. Lisa H. Jambusaria, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Akira W. Gillingham, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Elizabeth R. Burton, MD |
|
|
Dr. Stephen G. Somkuti, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Mitchell I. Edelson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joel I. Polin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Parviz Hanjani, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|